Trial · NCT07529938
Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy
NCT07529938, Completed, Chinese Academy of Medical Sciences, Fuwai Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy. Trials, record NCT07529938. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07529938
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy
- NCT number
- NCT07529938
- Status
- Completed
- Enrollment
- 222 participants, actual
- Lead sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Conditions
- Hypertrophic Cardiomyopathy (HCM), Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Interventions
- mavacamten
- First posted
- 2026-04-14
- Last updated
- 2026-04-17
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Resting Left Ventricular Outflow Tract (LVOT) Peak Gradient at Week 30 | Baseline to Week 30 | Change from baseline in resting left ventricular outflow tract (LVOT) peak gradient measured by Doppler echocardiography (unit: mmHg). Higher values indicate greater obstruction. |
| Secondary | Change in Valsalva-Induced Left Ventricular Outflow Tract (LVOT) Peak Gradient at Week 30 | Baseline to Week 30 | Change from baseline in LVOT peak gradient induced by the Valsalva maneuver measured by Doppler echocardiography (unit: mmHg). Higher values indicate greater obstruction. |
| Secondary | Proportion of Participants with Improvement in New York Heart Association (NYHA) Functional Classification at Week 30 | Baseline to Week 30 | Proportion of participants achieving at least one class improvement in New York Heart Association (NYHA) functional classification compared with baseline. NYHA class ranges from I to IV, where higher classes indicate worse functional status. |
| Secondary | Change in N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) Levels at Week 30 | Baseline to Week 30 | Change from baseline in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (unit: pg/mL). Higher values indicate worse cardiac function. |
| Secondary | Change in High-Sensitivity Cardiac Troponin I (hs-cTnI) Levels at Week 30 | Baseline to Week 30 | Change from baseline in high-sensitivity cardiac troponin I (hs-cTnI) levels (unit: ng/L). Higher values indicate greater myocardial injury. |
| Secondary | Change in Left Ventricular Ejection Fraction (LVEF) at Week 30 | Baseline to Week 30 | Change from baseline in left ventricular ejection fraction (LVEF) measured by echocardiography (unit: %). Higher values indicate better cardiac systolic function. |
| Secondary | Change in Tricuspid Annular Plane Systolic Excursion (TAPSE) at Week 30 | Baseline to Week 30 | Change from baseline in tricuspid annular plane systolic excursion (TAPSE) measured by echocardiography (unit: mm). Higher values indicate better right ventricular function. |
| Secondary | Incidence of Adverse Events | Up to Week 30 | Number and proportion of participants experiencing any adverse events. |
| Secondary | Incidence of Serious Adverse Events | Up to Week 30 | Number and proportion of participants experiencing serious adverse events. |
| Secondary | Incidence of Treatment Discontinuation Due to Adverse Events | Up to Week 30 | Number and proportion of participants who discontinued treatment due to adverse events. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07529938
GET https://conductscience.org/api/trials/v1/NCT07529938/registered